Changes in Bone Density in Carriers of BRCA1 and BRCA2 Pathogenic Variants After Salpingo-Oophorectomy
Authors: Chan Leslie N. , Chen Lee-may , Goldman Mindy , Mak Julie S. , Bauer Douglas C. , Boscardin John , Schembri Michael , Bae-Jump Victoria , Friedman Sue , Jacoby Vanessa L. 
Published: June 2023

OBJECTIVE:
To evaluate the effect of risk-reducing salpingo-oophorectomy (RRSO) on change in bone mineral density (BMD) in women aged 34–50 years with pathogenic variants in BRCA1 or BRCA2 (BRCA1/2).

METHODS:
The PROSper (Prospective Research of Outcomes after Salpingo-oophorectomy) study is a prospective cohort of women aged 34–50 years with BRCA1 or two germline pathogenic variants that compares health outcomes after RRSO to a non-RRSO control group with ovarian conservation. Women aged 34–50 years, who were planning either RRSO or ovarian conservation, were enrolled for 3 years of follow-up. Spine and total hip BMD were measured by dual-energy X-ray absorptiometry (DXA) scans obtained at baseline before RRSO or at the time of enrollment for the non-RRSO group, and then at 1 and 3 years of study follow-up. Differences in BMD between the RRSO and non-RRSO groups, as well as the association between hormone use and BMD, were determined by using mixed effects multivariable linear regression models.

RESULTS:
Of 100 PROSper participants, 91 obtained DXA scans (RRSO group: 40; non-RRSO group: 51). Overall, total spine, and hip BMD decreased significantly from baseline to 12 months after RRSO (estimated percent change −3.78%, 95% CI −6.13% to −1.43% for total spine; −2.96%, 95% CI −4.79% to −1.14% for total hip) and at 36 months (estimated percent change −5.71%, 95% CI −8.64% to −2.77% for total spine; −5.19%, 95% CI −7.50% to −2.87% for total hip. In contrast, total spine and hip BMD were not significantly different from baseline for the non-RRSO group. The differences in mean percent change in BMD from baseline between the RRSO and non-RRSO groups were statistically significant at both 12 and 36 months for spine BMD (12-month difference −4.49%, 95% CI −7.67% to −1.31%; 36-month difference −7.06%, 95% CI −11.01% to −3.11%) and at 36 months for total hip BMD (12-month difference −1.83%, 95% CI −4.23% to 0.56%; 36-month difference −5.14%, 95% CI −8.11% to −2.16%). Across the study periods, hormone use was associated with significantly less bone loss at both the spine and hip within the RRSO group compared with no hormone use (P<.001 at both 12 months and 36 months) but did not completely prevent bone loss (estimated percent change from baseline at 36 months −2.79%, 95% CI −5.08% to −0.51% for total spine BMD; −3.93%, 95% CI −7.27% to −0.59% for total hip BMD).

CONCLUSION:
Women with pathogenic variants in BRCA1/2 who undergo RRSO before the age of 50 years have greater bone loss after surgery that is clinically significant when compared with those who retain their ovaries. Hormone use mitigates, but does not eliminate, bone loss after RRSO. These results suggest that women who undergo RRSO may benefit from routine screening for BMD changes to identify opportunities for prevention and treatment of bone loss.

CLINICAL TRIAL REGISTRATION:

ClinicalTrials.gov, NCT01948609.